A study described a nanoparticle approach that targets scar-driving immune cells to open tumors to immunotherapy. The work focuses on the fibrotic tumor microenvironment—particularly in liver and lung cancers—where immune checkpoint inhibitors often fail because the matrix physically and immunologically walls off effector cells. By using nanoparticles designed to clear macrophage populations associated with fibrosis, researchers report improved access and an immunotherapy-permissive environment in preclinical models. The findings frame the strategy as a way to address the “fortress” created by chronic scarring rather than only trying to block tumor checkpoints. The report also underscores a common translational bottleneck in oncology: combinations need to tackle both tumor-intrinsic resistance and the non-malignant cell ecosystem that limits immune infiltration. If these macrophage-clearing concepts translate, they could become a modular addition for immunotherapy regimens in fibrotic solid tumors.